A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer

Lung Cancer

Volumn 66, Issue 3, 2009, Pages 365-371

  Bria, Emilio ^a   Milella, Michele ^a   Sperduti, Isabella ^a   Alessandrini, Gabriele ^a   Visca, Paolo ^a   Corzani, Felicita ^a   Giannarelli, Diana ^a   Cerasoli, Virna ^a   Cuppone, Federica ^a   Cecere, Fabiana Letizia ^a   Marchetti, Antonio ^b   Sacco, Rocco ^b   Mucilli, Felice ^b   Malatesta, Sara ^b   Guetti, Luigi ^b   Vitale, Luca ^b   Ceribelli, Anna ^a   Rinaldi, Massimo ^a   Terzoli, Edmondo ^a   Cognetti, Francesco ^a   Facciolo, Francesco ^a   more..

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

Classification; Early stage; Lung cancer; Lymph nodes; Prognosis; Surgery; Survival

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CAUSE SPECIFIC SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SURGERY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; RISK ASSESSMENT; SEX DIFFERENCE; SURVIVAL TIME;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPH NODES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS;

EID: 70350621634     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.02.024     Document Type: Article

References (33)

1. Gralow J., Ozols R.F., Bajorin D.F., et al. Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening-a report from the American Society of Clinical Oncology. J Clin Oncol 26 (2008) 313-325
2. Jemal A., Siegel R., Ward E., et al. Cancer statistics 2007. CA Cancer J Clin 57 (2007) 43-66
3. Spira A., and Ettinger D.S. Multidisciplinary management of lung cancer. N Engl J Med 350 (2004) 379-392
4. Rusch V.W., Crowley J., Giroux D.J., et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 2 (2007) 603-612
5. Gajra A., Newman N., Gamble G.P., et al. Effect of number of lymph nodes sampled on outcome in patients with stage I non-small-cell lung cancer. J Clin Oncol 21 (2003) 1029-1034
6. Scott W.J., Howington J., Feigenberg S., et al. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132 (2007) 234S-242S
7. Luzzi L., Paladini P., Ghiribelli C., et al. Assessing the prognostic value of the extent of mediastinal lymph node infiltration in surgically-treated non-small cell lung cancer (NSCLC). Lung Cancer 30 (2000) 99-105
8. McNeil C. New NSCLC staging raises treatment issues. J Natl Cancer Inst 99 (2007) 1748-1749
9. Arriagada R., Bergman B., Dunant A., et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350 (2004) 351-360
10. Douillard J.Y., Rosell R., De Lena M., et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 7 (2006) 719-727
11. Winton T., Livingston R., Johnson D., et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352 (2005) 2589-2597
12. Johnson P.M., Porter G.A., Ricciardi R., and Baxter N.N. Increasing negative lymph node count is independently associated with improved long-term survival in stage IIIB and IIIC colon cancer. J Clin Oncol 24 (2006) 3570-3575
13. Karlsson P., Cole B.F., Price K.N., et al. The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer. J Clin Oncol 25 (2007) 2019-2026
14. Kassouf W., Agarwal P.K., Herr H.W., et al. Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC. J Clin Oncol 26 (2008) 121-126
15. Iasonos A., Schrag D., Raj G.V., and Panageas K.S. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol 26 (2008) 1364-1370
16. Cahan W.G., Watson W.L., and Pool J.L. Radical pneumonectomy. J Thorac Surg 22 (1951) 449-473
17. Martini N., and Flehinger B.J. The role of surgery in N2 lung cancer. Surg Clin North Am 67 (1987) 1037-1049
18. Naruke T. Mediastinal lymph node dissection. In: Shields TW, editor. General thoracic surgery, 5th ed. Philadelphia: Lippincott Williams and Wilkins 2000. p. 1343-56.
19. Shuster J.J. Median follow-up in clinical trials. J Clin Oncol 9 (1991) 191-192
20. Cox D.R. Regression models and life tables. J Royal Stat Soc 4 (1972) 187-200
21. Hess K.R. Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med 14 (1995) 1707-1723
22. Kaplan E.L., and Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
23. Sauerbrei W., and Schumacher M. A bootstrap resampling procedure for model building: application to the Cox regression model. Stat Med 11 (1992) 2093-2109
24. Efficace F., Bottomley A., Smit E.F., et al. Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. Ann Oncol 17 (2006) 1698-1704
25. Network NCC. NCCN Clinical Practice Guidelines in Oncology - Non-Small-Cell Lung Cancer. V.2.2008. In Edition 2008.
26. Asamura H., Goya T., Koshiishi Y., et al. A Japanese Lung Cancer Registry study: prognosis of 13 010 resected lung cancers. J Thorac Oncol 3 (2008) 46-52
27. Ingle A.M., Kumar P., Griggs M.M., et al. Impact of number of lymph nodes (LN) examined at the time of surgical resection (Sx) on the survival of stage IA non-small cell lung cancer (NSCLC) patients (pts). J Clin Oncol (Meeting Abstracts) 26 (2008) 7534
28. Goldstraw P., Crowley J., Chansky K., et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2 (2007) 706-714
29. Pignon J.P., Tribodet H., Scagliotti G.V., et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 26 (2008) 3552-3559
30. Le Chevalier T, Dunant A, Arriagada R et al. Long-term results of the International Adjuvant Lung Cancer Trial (IALT) evaluating adjuvant cisplatin-based chemotherapy in resected non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 2008;26:7507.
31. Chen H.Y., Yu S.L., Chen C.H., et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 356 (2007) 11-20
32. Lau S.K., Boutros P.C., Pintilie M., et al. Three-gene prognostic classifier for early-stage non small-cell lung cancer. J Clin Oncol 25 (2007) 5562-5569
33. Bianchi F., Nuciforo P., Vecchi M., et al. Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. J Clin Invest 117 (2007) 3436-3444